INmune Bio Completes Blinded Interim Analysis Of Its Phase II Alzheimer's Disease Trial, Says 'The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint.'
Portfolio Pulse from Benzinga Newsdesk
INmune Bio has completed a blinded interim analysis of its Phase II Alzheimer's Disease trial, confirming the accuracy of sample size calculations and statistical power for the primary endpoint, EMACC.
June 27, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INmune Bio has successfully completed a blinded interim analysis of its Phase II Alzheimer's Disease trial, confirming the accuracy of sample size calculations and statistical power for the primary endpoint, EMACC.
The successful completion of the interim analysis and confirmation of the trial's statistical power and sample size accuracy is a positive development for INmune Bio. This increases the likelihood of achieving the primary endpoint, which could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100